Rituxan gets expanded US lymphoma indication
This article was originally published in Scrip
Executive Summary
The US FDA has approved an additional indication for Roche and Biogen Idec's Rituxan (rituximab) for maintenance treatment for patients with advanced follicular lymphoma who responded to initial treatment with rituximab plus chemotherapy.